Aikema Medical Secures Additional RMB 50 Million Investment from Lanwan Sci-Tech Group to Advance Domestic Pulsed Field Ablation and 3D Mapping Systems
AccuPulse
Developer of products in the field of cardiac electrophysiology
VCBeat learned exclusively that, following2Monthly CompletionAccuPulseShanghai Biopharmaceutical Fund andShengshi Investment Management's Shaoxing Binhai New Area Biomedical Industry Equity Investment FundCo-led byRecently2100 million yuanA+After the round of financing,AccuPulse Medical Technology Co., Ltd. (referred to as“AccuPulse”) recently announced the completionBlue Bay Sci-Tech Group5000Additional investment of tens of millions. This round of financing will still be used to promote the research and development and commercialization of the company's core products, pulsed field ablation and 3D mapping systems.Operation.
AccuPulse Medical Technology Co., Ltd. was founded in November 2020, committed to the innovative platform technology in the field of cardiac electrophysiology. The company has assembled a research and development team led by well-known electrophysiology technology experts from the United States, and has received strong support from returning overseas scientists, renowned clinical experts, and venture capital institutions. Its R&D centers are located in Suzhou and the United States.
AccuPulse has established nearly 10 product pipelines based on new technologies such as pulsed field ablation (PFA) and innovative 3D mapping, covering the complete process of diagnosis and treatment for arrhythmia ablation, including atrial fibrillation and premature ventricular contractions. In April 2023, AccuPulse's self-developed pulsed field ablation system successfully completed the enrollment for all clinical studies, placing it in the first tier of clinical research for pulsed field products both domestically and internationally. It is planned to be launched simultaneously with AccuPulse’s self-developed cardiac 3D mapping system in 2025.
AccuPulse Pulsed Electric Field Ablation System
The AccuPulse pulsed ablation system, independently developed by AccuPulse Medical, is designed with a catheter-to-myocardium contact indication feature that helps doctors assess the contact status between the catheter tip and target tissue. Additionally, the system features an adjustable loop diameter at the catheter tip to accommodate pulmonary veins of varying sizes while maintaining compatibility with commonly used three-dimensional mapping systems in clinical practice. This system entered the special review channel for innovative medical devices in February this year and is about to enter the registration approval stage soon.
It is reported that the system has completed clinical research at eight research centers in China, with 18 electrophysiology experts. The immediate success rate during the operation reached 100%, and the effective rate of 12-month long-term follow-up has reached 87.7%. The quality of life of patients after surgery has been significantly improved.
And in the just-passed May, AccuPulse Medical Technology Co., Ltd. showcased its pulsed field ablation catheter and high-density mapping catheter at the Heart Rhythm Society 2024 (HRS 2024). Its variable loop diameter ablation catheter and uniquely designed high-density mapping catheter attracted domestic and international electrophysiology experts and peers to stop by.
AccuPulse HRS Booth Attracts Renowned Physicians from China and Abroad
At this HRS conference, the team led by Jiang Chenyang from Sir Run Run Shaw Hospital shared the 12-month follow-up results of treating atrial fibrillation with the AccuPulse system. The results met expectations, with a success rate exceeding 86%, demonstrating better efficacy compared to similar products.
Sir Run Run Shaw Hospital's Jiang Chenyang Team Shares at HRS 2024
Regarding the acquisition of this round of financing,Founder of AccuPulseExpressed: "Thanks to Blue Bay Sci-Tech Group and all the old shareholders for their recognition and continuous support of AccuPulse. We are greatly honored to be favored by these visionary and courageous 'patient capitals', and also feel a significant responsibility. We firmly believe that pulse field ablation combined with 3D mapping systems is the future direction of electrophysiology technology development. The AccuPulse team will continue on the path of disruptive innovation and internationalization, bringing better solutions to the vast number of patients with arrhythmia and creating greater value for shareholders."
Deng Jianxin, Founder of Blue Bay Innovation GroupExpressed: "AccuPulse demonstrates strong innovation capabilities and has an excellent team. The market prospects for applying PFA in atrial fibrillation treatment are broad. With the company's superior clinical data for its PFA products and the support of its three-dimensional mapping system, it is expected that the company will possess strong competitiveness. We have great confidence in the AccuPulse team led by Mr. Yin, and believe that AccuPulse will grow into a representative Chinese innovative medical device enterprise with international competitiveness."
About Blue Bay Sci-Tech Group
Blue Bay Sci-Tech Group is an innovative industrial ecosystem operator focusing on the life and health industry. With the basic business model of "industry + platform + capital + operation," it centers on industrial investment, with industrial operation and industrial services as its two wings, and is committed to building a regional innovation and entrepreneurship ecosystem that meets the Blue Bay standard.
Blue Bay Sci-Tech currently manages 5 industrial funds with a total scale exceeding 2 billion yuan, focusing on early-stage investments, particularly angel round projects. It has cumulatively invested in more than 50 high-tech life science and health projects. Investment cases include Aosikang Biopharmaceuticals, Jingze Biotech, Yiying Technology, Haitai Biotech, Nolaisound Technology, Huyun New Drug, Notan Pharmaceuticals, Huiwei Medical, Tanyin Medicine, Tongxuan Medical, Yike Polymers, Hannuclear Medical, and Dassence Medical.
At the same time, Blue Bay Sci-Tech is deeply involved in the comprehensive development and operation of regional areas, always adhering to the concept of "industry as the foundation, talent as the base, ecology as the soul, platform as the tool, capital as the core, and operation as the king". It has assisted the government in building characteristic industrial clusters such as the Haimen Biomedical Town, Xianju Medical Device Town, Hanzhong Nuclear Medicine Industrial Park, Dongying Animal Protection Biomedical Industrial Park, striving to become the best accelerator in China's biomedicine field.
Related Reading: